Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.65 |
| ▸ | FNTA | P49354 | 6/20 | 0.61 |
| ▸ | FNTB | P49356 | 4/20 | 0.61 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.61 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795540 | 1.00 | TRPA1 (0.65) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL13146318 | 1.00 | TRPA1 (0.65) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL10871808 | 0.98 | FNTA (0.64) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL10048261 | 0.98 | FNTA (0.64) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL13142544 | 0.98 | FNTA (0.64) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL7617399 | 0.98 | FNTA (0.64) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL2568553 | 0.88 | TRPA1 (0.65) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL2571319 | 0.88 | TRPA1 (0.65) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL2568549 | 0.88 | TRPA1 (0.65) | TRPA1FNTAFNTBPGGT1BTRPV1 | |
| SCHEMBL2352098 | 0.86 | TRPA1 (0.63) | TRPA1FNTAFNTBPGGT1BTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | claimed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | claimed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | claimed |
| US-9688651-B2 | Geranyl geranyl acetone analogs and uses thereof | NYKEN HOLDING B.V. (NL) | 2017-06-27 | — | — | US | disclosed |
| US-20150152076-A1 | Geranyl Geranyl Acetone Analogs and Uses Thereof | NYKEN HOLDING B.V. (NL) | 2015-06-04 | — | — | US | disclosed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| EP-2616056-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | Neuroquest Inc. (CA) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012034232-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | NEUROQUEST INC. (CA) | 2012-03-22 | — | — | WO | disclosed |
| US-7794768-B2 | Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7794768-B2 | Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20080317922-A1 | SATURATED AND UNSATURATED N-ALKAMIDES EXHIBITING TASTE AND FLAVOR ENHANCEMENT EFFECT IN FLAVOR COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-12-25 | — | — | US | disclosed |
| US-20080317922-A1 | SATURATED AND UNSATURATED N-ALKAMIDES EXHIBITING TASTE AND FLAVOR ENHANCEMENT EFFECT IN FLAVOR COMPOSITIONS | INTERNATIONAL FLAVORS & FRAGRANCES INC. | 2008-12-25 | — | — | US | disclosed |
| US-7427421-B2 | Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427421-B2 | Saturated and unsaturated N-alkamides exhibiting taste and flavor enhancement effect in flavor compositions | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2008-09-23 | — | — | US | disclosed |
| WO-1996016957-A1 | 3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-BENZOPYRAN-6-OL DERIVATIVES FOR USE AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1996-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152076-A1 | Geranyl Geranyl Acetone Analogs and Uses Thereof | HSF1, XBP1, HSPB1 | TRPA1 89/4885FNTA 57/4885FNTB 134/4885 |
| US-20080317922-A1 | SATURATED AND UNSATURATED N-ALKAMIDES EXHIBITING TASTE AND FLAVOR ENHANCEMENT EFFECT IN FLAVOR COMPOSITIONS | TAS2R8, TAS2R3, TAS2R5 | TRPA1 49/4885FNTA 3503/4885FNTB 3830/4885 |
| US-20130267571-A1 | TERPENOID ANALOGUES AND USES THEREOF FOR TREATING NEUROLOGICAL CONDITIONS | PMP22, PTGES, GGPS1 | TRPA1 40/4885FNTA 46/4885FNTB 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.